JP2004532218A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532218A5 JP2004532218A5 JP2002580900A JP2002580900A JP2004532218A5 JP 2004532218 A5 JP2004532218 A5 JP 2004532218A5 JP 2002580900 A JP2002580900 A JP 2002580900A JP 2002580900 A JP2002580900 A JP 2002580900A JP 2004532218 A5 JP2004532218 A5 JP 2004532218A5
- Authority
- JP
- Japan
- Prior art keywords
- sustained release
- poly
- release composition
- pharmaceutical composition
- biocompatible polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 28
- 238000013268 sustained release Methods 0.000 claims 25
- 239000012730 sustained-release form Substances 0.000 claims 25
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 229920000249 biocompatible polymer Polymers 0.000 claims 15
- 229940122361 Bisphosphonate Drugs 0.000 claims 11
- -1 bisphosphonate compound Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229920001710 Polyorthoester Polymers 0.000 claims 4
- 229920001577 copolymer Polymers 0.000 claims 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 239000010979 ruby Substances 0.000 claims 3
- 229910001750 ruby Inorganic materials 0.000 claims 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 2
- 229920002732 Polyanhydride Polymers 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 229920000954 Polyglycolide Polymers 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 229920002988 biodegradable polymer Polymers 0.000 claims 2
- 239000004621 biodegradable polymer Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims 2
- 229920000117 poly(dioxanone) Polymers 0.000 claims 2
- 229940065514 poly(lactide) Drugs 0.000 claims 2
- 229920000515 polycarbonate Polymers 0.000 claims 2
- 239000004417 polycarbonate Substances 0.000 claims 2
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000004814 polyurethane Substances 0.000 claims 2
- 229920002635 polyurethane Polymers 0.000 claims 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims 1
- 229940062527 alendronate Drugs 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 229940009626 etidronate Drugs 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 229940046231 pamidronate Drugs 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229940019375 tiludronate Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/835,001 US6558702B2 (en) | 2001-04-13 | 2001-04-13 | Method of modifying the release profile of sustained release compositions |
| PCT/US2002/008440 WO2002083096A1 (en) | 2001-04-13 | 2002-03-19 | Modification of the sustained release profile |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004532218A JP2004532218A (ja) | 2004-10-21 |
| JP2004532218A5 true JP2004532218A5 (enExample) | 2005-12-22 |
Family
ID=25268316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002580900A Pending JP2004532218A (ja) | 2001-04-13 | 2002-03-19 | 徐放性プロフィールの変更 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US6558702B2 (enExample) |
| EP (1) | EP1395240A4 (enExample) |
| JP (1) | JP2004532218A (enExample) |
| AU (1) | AU2002244314B2 (enExample) |
| CA (1) | CA2444421A1 (enExample) |
| WO (1) | WO2002083096A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6824822B2 (en) * | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
| US20060269602A1 (en) * | 2001-04-13 | 2006-11-30 | Dasch James R | Method of modifying the release profile of sustained release compositions |
| US6558702B2 (en) * | 2001-04-13 | 2003-05-06 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
| US20030118630A1 (en) * | 2001-12-07 | 2003-06-26 | Anthony Cerami | Immune modulation device for use in animals |
| CN1194688C (zh) * | 2001-07-03 | 2005-03-30 | 山东绿叶制药股份有限公司 | 石杉碱甲及其衍生物或其盐的注射用缓释微球及其制备方法 |
| US6818613B2 (en) * | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
| WO2004089345A1 (en) * | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals Inc. | Bone targeting of biodegradable drug-containing nanoparticles |
| US10517883B2 (en) | 2003-06-27 | 2019-12-31 | Zuli Holdings Ltd. | Method of treating acute myocardial infarction |
| HRP20110831T1 (hr) | 2004-04-15 | 2012-01-31 | Alkermes Pharma Ireland Limited | Oblik za produljeno oslobađanje na bazi polimera |
| US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
| US20060110423A1 (en) * | 2004-04-15 | 2006-05-25 | Wright Steven G | Polymer-based sustained release device |
| KR100648515B1 (ko) * | 2004-05-04 | 2006-11-27 | (주)아모레퍼시픽 | 비스포스포네이트-함유 고분자 미립구를 포함하는 골-관련질환 치료 또는 예방용 서방 효과를 갖는 주사제 |
| WO2005107714A2 (en) * | 2004-05-05 | 2005-11-17 | Alkermes Controlled Therapeutics, Inc. | Method of forming microparticles that include a bisphosphonate and a polymer |
| US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
| WO2006014673A2 (en) | 2004-07-19 | 2006-02-09 | Nobex Corporation | Insulin-oligomer conjugates, formulations and uses thereof |
| WO2006036834A2 (en) * | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
| WO2006078841A1 (en) * | 2005-01-21 | 2006-07-27 | President And Fellows Of Harvard College | Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles |
| US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
| EP1865928A1 (en) * | 2005-03-17 | 2007-12-19 | Elan Pharma International Limited | Nanoparticulate biphosphonate compositions |
| US7815667B2 (en) * | 2005-07-21 | 2010-10-19 | Pyles Stephen T | Power source for an implantable medical device |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| US20100166865A1 (en) * | 2006-08-17 | 2010-07-01 | Novartis Ag | Nanoparticle compositions |
| US8974801B2 (en) * | 2006-12-21 | 2015-03-10 | Amphastar Pharmaceuticals Inc. | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
| EP2131815A4 (en) * | 2007-03-22 | 2012-11-07 | Alkermes Inc | coacervation |
| CA2687979C (en) * | 2007-05-25 | 2017-07-04 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of risperidone compounds |
| WO2008157540A1 (en) * | 2007-06-20 | 2008-12-24 | Alkermes, Inc. | Quench liquids and washing systems for production of microparticles |
| CN102105133B (zh) * | 2008-07-21 | 2015-06-17 | 奥德纳米有限公司 | 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法 |
| US20100189800A1 (en) * | 2009-01-23 | 2010-07-29 | Peter Markland | Continous double emulsion process for making microparticles |
| US20100247607A1 (en) * | 2009-03-26 | 2010-09-30 | Psivida Us, Inc. | Implantable formulations of bisphosphonic acids |
| GB2481017B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| US8858979B1 (en) | 2011-01-28 | 2014-10-14 | Clemson University | Service induced byproducts for localized drug delivery in orthopaedic implants |
| PL3199146T3 (pl) | 2011-04-25 | 2020-03-31 | Shan Dong Luye Pharmaceutical Co., Ltd. | Kompozycja mikrosfery rysperydonu o przedłużonym uwalnianiu |
| EP2931300A1 (en) | 2012-08-14 | 2015-10-21 | Wockhardt Limited | Pharmaceutical microparticulate compositions of polypeptides |
| EP2934562A1 (en) | 2012-08-14 | 2015-10-28 | Wockhardt Limited | Pharmaceutical microparticulate compositions of polypeptides |
| US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| AU2015341490C1 (en) | 2014-11-07 | 2021-03-11 | Indivior Uk Limited | Buprenorphine dosing regimens |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE634668A (enExample) | 1962-07-11 | |||
| BE744162A (fr) | 1969-01-16 | 1970-06-15 | Fuji Photo Film Co Ltd | Procede d'encapsulage |
| DE2010115A1 (de) | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Mikrogranulaten |
| JPS523342B2 (enExample) | 1972-01-26 | 1977-01-27 | ||
| GB1413186A (en) | 1973-06-27 | 1975-11-12 | Toyo Jozo Kk | Process for encapsulation of medicaments |
| DE2943498C2 (de) | 1979-10-27 | 1983-01-27 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure |
| US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| FR2531088B1 (fr) | 1982-07-29 | 1987-08-28 | Sanofi Sa | Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation |
| IT1196315B (it) | 1984-10-29 | 1988-11-16 | Gentili Ist Spa | Procedimento per la preparazione di acidi difosfonici |
| IL77243A (en) | 1984-12-21 | 1996-11-14 | Procter & Gamble | Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds |
| JPH02178243A (ja) * | 1988-12-28 | 1990-07-11 | Kurita Water Ind Ltd | ２，２’―ビス（α―ヒドロキシジフェニルメチル）ビフェニル及びそれから成るホスト化合物 |
| US5019400A (en) | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
| US4922007A (en) | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| US5196409A (en) | 1989-08-20 | 1993-03-23 | Yissum, Research Development Company Of The Hebrew University Of Jerusalem | Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism |
| IL91362A0 (en) | 1989-08-20 | 1990-03-19 | Yissum Res Dev Co | Bisphosphonates,process for preparing them and pharmaceutical compositions containing them |
| US5019651A (en) | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
| JPH06500112A (ja) | 1990-08-21 | 1994-01-06 | ジ・アップジョン・カンパニー | 抗関節炎剤としてのビスホスホン酸誘導体 |
| US5656297A (en) | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5711968A (en) | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
| US5700485A (en) | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
| AU683022B2 (en) | 1992-09-10 | 1997-10-30 | Children's Medical Center Corporation | Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
| ES2151541T3 (es) | 1992-12-02 | 2001-01-01 | Alkermes Inc | Microesferas que contienen hormona del crecimiento de liberacion prolongada. |
| US6399592B1 (en) * | 1992-12-23 | 2002-06-04 | Merck & Co., Inc. | Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss |
| US5861168A (en) * | 1993-06-11 | 1999-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
| US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
| US6117455A (en) * | 1994-09-30 | 2000-09-12 | Takeda Chemical Industries, Ltd. | Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent |
| US5922253A (en) | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
| AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US6123964A (en) * | 1995-10-27 | 2000-09-26 | Merck & Co., Inc. | Wet granulation formulation of a growth hormone secretagogue |
| US5885973A (en) | 1995-12-27 | 1999-03-23 | Gador, S.A. | Bone mass anabolic composition comprising olpadronate |
| US6117856A (en) | 1996-02-14 | 2000-09-12 | Binderman; Itzhak | Topical bisphosphonates for prevention of bone resorption |
| IL120270A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis |
| EP0839525B1 (en) * | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6080779A (en) | 1996-12-13 | 2000-06-27 | Osteoscreen, Inc. | Compositions and methods for stimulating bone growth |
| US6070779A (en) * | 1997-02-06 | 2000-06-06 | U.S. Philips Corporation | Liquid dosing device |
| BR9810027A (pt) | 1997-06-11 | 2000-09-12 | Procter & Gamble | Comprimido revestido por pelìcula para melhorada segurança do trato gastrintestinal superior |
| US6162929A (en) | 1997-12-23 | 2000-12-19 | Hoffmann-La Roche Inc. | Process for the manufacture of bisphosphine oxide and bisphosphonate compounds |
| EP1365770A2 (en) * | 2001-02-07 | 2003-12-03 | Durect Corporation | Devices and methods for management of bone density |
| US6558702B2 (en) * | 2001-04-13 | 2003-05-06 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
-
2001
- 2001-04-13 US US09/835,001 patent/US6558702B2/en not_active Expired - Fee Related
-
2002
- 2002-03-19 EP EP02709857A patent/EP1395240A4/en not_active Withdrawn
- 2002-03-19 WO PCT/US2002/008440 patent/WO2002083096A1/en not_active Ceased
- 2002-03-19 JP JP2002580900A patent/JP2004532218A/ja active Pending
- 2002-03-19 CA CA002444421A patent/CA2444421A1/en not_active Abandoned
- 2002-03-19 AU AU2002244314A patent/AU2002244314B2/en not_active Ceased
-
2003
- 2003-03-25 US US10/400,162 patent/US20030236192A1/en not_active Abandoned
-
2004
- 2004-01-16 US US10/758,717 patent/US7074432B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004532218A5 (enExample) | ||
| EP2079491B1 (en) | N-substituted monomers and polymers | |
| CA3029961C (en) | Biocompatible polymers for medical devices | |
| EP0656026B1 (en) | Polyarylates containing derivatives of the natural amino acid l-tyrosine | |
| JP5944314B2 (ja) | 医療装置のための生体適合性ポリマー | |
| JP2002542341A5 (enExample) | ||
| JP2005504797A5 (enExample) | ||
| HRP20150272T1 (hr) | Oblik s produljenim oslobađanjem na bazi polimera | |
| CN1256701A (zh) | 由磷酸酯扩链的生物降解聚合物、组合物、制品及其制备和使用方法 | |
| CN102186484A (zh) | Aabb-聚(酯肽)可生物降解聚合物及其使用方法 | |
| CZ20033479A3 (cs) | Lipid-polymerové konjugáty | |
| AU2015370426B2 (en) | Biocompatible iodinated diphenol monomers and polymers | |
| Katsarava et al. | Biodegradable Polymers Composed of Naturally Occurring α‐Amino Acids | |
| CN1957021A (zh) | pH值和温度敏感性水凝胶 | |
| EP2331075B1 (en) | Controlled-released peptide formulations | |
| Tsung et al. | Biodegradable polymers in drug delivery systems | |
| JP2016502608A (ja) | 薬物送達のためのポリエステルアミドコポリマーを含む繊維 | |
| US20040258730A1 (en) | Persistent filmy preparation for topical administration containing prostglandin derivative | |
| JPH0667886B2 (ja) | 高分子化合物 | |
| Papathanasiou et al. | Polymeric matrices for the controlled release of phosphonate active agents for medicinal applications | |
| Zavradashvili et al. | New Cationic Polymers Composed of Non-Proteinogenic α-Amino Acids | |
| AU2015202526B2 (en) | Biocompatible polymers for medical devices | |
| HK1157212B (en) | Controlled-released peptide formulations | |
| TH76143A (th) | สารผสมที่มีการปลดปล่อยแบบเนิ่น, กระบวนการสำหรับการผลิตสารชนิดเดียวกัน และการใช้สารชนิดเดียวกัน | |
| JP2007056046A (ja) | 温度応答性及び生分解性ポリデプシペプチド並びにその製造方法 |